This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Diabetes Mellitus  • Adverse Effects  • Alert me on articles by topic

Lisa M. Sommers, BS; Robert B. Schoene, MD

Arch Intern Med. 2002;162:1190-1192.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Allopurinol, a xanthine oxidase inhibitor, has been in use since 1963 as an effective treatment to lower uric acid levels in patients with gout.¹ Severe and occasionally fatal adverse reactions have been attributed to allopurinol use in 1 of 260 patients and include agranulocytosis, granulomatous hepatitis, and a systemic hypersensitivity syndrome known as the allopurinol hypersensitivity syndrome (AHS),² which most frequently develops within days to weeks after initiating allopurinol therapy.³ The syndrome initially manifests with a rash, ranging from an intensely pruritic maculopapular rash to toxic epidermal necrolysis.³ Associated with rash are fever, leukocytosis, eosinophilia, evidence of acute hepatic injury, and renal dysfunction.^{1, 3-4} We describe for the first time a patient with AHS who, along with having the common features of AHS, developed concurrent elevations in pancreatic exocrine enzyme level and new-onset type 1 diabetes mellitus.

REPORT OF A CASE

While receiving treatment for hypertension, a . . . [Full Text of this Article]

COMMENT

From the Department of Medicine, University of Washington School of Medicine, Seattle.